Share on LinkedInShare on LinkedIn

ARTICLE · 05 SEPTEMBER 2018

CJEU Issues Landmark Decision On Patent Term Extensions For Medicinal Products

The UK High Court asked the CJEU what the criteria were for deciding whether a product is protected by a basic patent pursuant to Article 3(a) of Regulation No. 469/2009.

European UnionIntellectual Property

The Court of Justice of the European Union (CJEU) rendered a landmark decision extending patent term extensions for certain medicinal products in litigation relating to supplementary protection certificates (SPCs) for the blockbuster anti-HIV drug TRUVAD. Teva UK Ltd., et al. v. Gilead Sciences Inc., Case No. C 121/17 (CJEU July 25, 2018) (Grand Chamber).

SPCs are special national intellectual property rights in the European Economic Area that extend the term of certain rights associated with patents granted for human or veterinary medicinal and plant protection products. An SPC does not extend the term of protection of a basic patent as such; the protection conferred by an SPC is rather limited to a certain product for which market authorization has been obtained. SPCs were introduced to compensate innovative parties for the significant time necessary to obtain such market authorizations.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from